Next Article in Journal
Neuronal Ceroid Lipofuscinoses: Connecting Calcium Signalling through Calmodulin
Next Article in Special Issue
Mechanism of Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors and a Potential Treatment Strategy
Previous Article in Journal / Special Issue
Characterization and Drug Sensitivity of a New High-Grade Myxofibrosarcoma Cell Line
Article Menu
Issue 11 (November) cover image

Export Article

Open AccessArticle
Cells 2018, 7(11), 187;

PET Imaging Biomarkers of Anti-EGFR Immunotherapy in Esophageal Squamous Cell Carcinoma Models

Division of RI Application, Korea Institute of Radiological and Medical Sciences (KIRAMS), Seoul 01812, Korea
Department of Biomedical Laboratory Science, College of Health Science, Yonsei University, Wonju 26493, Korea
Author to whom correspondence should be addressed.
Received: 10 October 2018 / Revised: 24 October 2018 / Accepted: 26 October 2018 / Published: 27 October 2018
(This article belongs to the Special Issue Epidermal Growth Factor Receptor Signaling)
PDF [3605 KB, uploaded 27 October 2018]


Epidermal growth factor receptor (EGFR) is overexpressed and considered as a proper molecular target for diagnosis and targeted therapy of esophageal squamous cell carcinoma (ESCC). This study evaluated the usefulness of PET imaging biomarkers with 64Cu-PCTA-cetuximab and 18F-FDG-PET for anti-EGFR immunotherapy in ESCC models. In vivo EGFR status and glucose metabolism by cetuximab treatment were evaluated using 64Cu-PCTA-cetuximab and 18F-FDG-PET, respectively. Therapeutic responses with imaging biomarkers were confirmed by western blot and immunohistochemistry. TE-4 and TE-8 tumors were clearly visualized by 64Cu-PCTA-cetuximab, and EGFR expression on TE-8 tumors showed 2.6-fold higher uptake than TE-4. Tumor volumes were markedly reduced by cetuximab in TE-8 tumor (92.5 ± 5.9%), but TE-4 tumors were refractory to cetuximab treatment. The SUVs in 64Cu-PCTA-cetuximab and 18F-FDG-PET images were statistically significantly reduced by cetuximab treatment in TE-8 but not in TE-4. 64Cu-PCTA-cetuximab and 18F-FDG-PET images were well correlated with EGFR and pAkt levels. 64Cu-PCTA-cetuximab immuno-PET had a potential for determining EGFR level and monitoring therapeutic response by anti-EGFR therapy. 18F-FDG-PET was also attractive for monitoring efficacy of anti-EGFR therapy. In conclusion, PET imaging biomarkers may be useful for selecting patients that express target molecules and for monitoring therapeutic efficacy of EGFR-targeted therapy in ESCC patients. View Full-Text
Keywords: EGFR; cetuximab; PET; imaging biomarker; Cu-64; 18F-FDG EGFR; cetuximab; PET; imaging biomarker; Cu-64; 18F-FDG

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Supplementary material


Share & Cite This Article

MDPI and ACS Style

Lee, T.S.; Song, I.H.; Shin, J.I.; Park, Y.S.; Kim, J.Y.; Kim, K.I.; Lee, Y.J.; Kang, J.H. PET Imaging Biomarkers of Anti-EGFR Immunotherapy in Esophageal Squamous Cell Carcinoma Models. Cells 2018, 7, 187.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Cells EISSN 2073-4409 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top